Table of contents

Clinical and epidemiological research

• Extended report: Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study (23 March, 2016)

  Munther Khamashta, Joan T Merrill, Victoria P Werth, Richard Furie, Kenneth Kalunian, Gabor G Illei, Jorn Drappa, Liangwei Wang, Warren Greth
• Extended report: Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study) (5 January, 2016)

  Yuko Kaneko, Tatsuya Atsumi, Yoshiya Tanaka, Masayuki Inoo, Hitomi Kobayashi-Haraoka, Koichi Amano, Masayuki Miyata, Yohko Murakawa, Hidekata Yasuoka, Shintaro Hirata, Hayato Nagasawa, Eiichi Tanaka, Nobuyuki Miyasaka, Hisashi Yamanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi
• Extended report: Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts (12 January, 2016)

  S Ajeganova, J H Humphreys, M K Verheul, H W van Steenbergen, J A B van Nies, I Hafström, B Svensson, T W J Huizinga, L A Trouw, S M M Verstappen, A H M van der Helm-van Mil
• Extended report: Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment (12 January, 2016)

  Konstantina Delli, Erlin A Haacke, Frans G M Kroese, Rodney P Pollard, Stephan Ihrler, Bert van der Vegt, Arjan Vissink, Hendrika Bootsma, Frederik K L Spijkervet
• Extended report: Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study (13 January, 2016)

  Wietske Kievit, Noortje van Herwaarden, Frank HJ van den Hoogen, Ronald F van Vollenhoven, Johannes WJ Bijlsma, Bart JF van den Bemt, Aatke van der Maas, Alfons A den Broeder
• Extended report: Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies (25 January, 2016)

  Raphaèle Seror, Petra Meiners, Gabriel Baron, Hendrika Bootsma, Simon J Bowman, Claudio Vitali, Jacques-Eric Gottenberg, Elke Theander, Athanasios Tzioufas, Salvatore De Vita, Manel Ramos-Casals, Thomas Dörner, Luca Quartuccio, Philippe Ravaud, Xavier Mariette
• Extended report: Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim (21 January, 2016)

  Sovira Tan, Abhijit Dasgupta, Jianhua Yao, John A Flynn, Lawrence Yao, Michael M Ward
• Extended report: Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group (14 January, 2016)

  Robert G W Lambert, Pauline A C Bakker, Désirée van der Heijde, Ulrich Weber, Martin Rudwaleit, Kay-Geert A Hermann, Joachim Sieper, Xenofon Baraliakos, Alex Bennett, Jürgen Braun, Rubén Burgos-Vargas, Maxime Dougados, Susanne Juhl Pedersen, Anne Grethe Jurik, Walter P Maksymowych, Helena Marzo-Ortega, Mikkel Østergaard, Denis Poddubnyy, Monique Reijnierse, Filip van den Bosch, Irene van der Horst-Bruinsma, Robert Landewé
• Extended report: Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials (16 February, 2016)

  Kun Zou, Jean Wong, Natasya Abdullah, Xi Chen, Toby Smith, Michael Doherty, Weiya Zhang
• Extended report: Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis (16 February, 2016)

  Toby O Smith, Kun Zou, Natasya Abdullah, Xi Chen, Sarah R Kingsbury, Michael Doherty, Weiya Zhang, Philip G Conaghan
• Concise report: Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings (15 April, 2016)

  Mark C Genovese, Fang Yang, Mikkel Østergaard, Nils Kinnman
• Concise report: Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2) (20 April, 2016)

  Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, Christopher Ritchlin, Yin You, Shu Li, Michael Song, Bruce Randazzo, Proton Rahman, Iain B McInnes